NCT04367311: An ongoing trial by Nasser Hanna
This trial is ongoing. It must report results 9 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04367311 |
|---|---|
| Title | A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) Big Ten Cancer Research Consortium BTCRC-LUN19-396 |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 22, 2020 |
| Completion date | Sept. 30, 2025 |
| Required reporting date | Sept. 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |